Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Nggt (suzhou) Biotechnology Co., Ltd.

Clinical trials sponsored by Nggt (suzhou) Biotechnology Co., Ltd., explained in plain language.

Upcoming readouts

Trials from this sponsor expected to report results within the next 12 months.

Can a One-Time gene infusion rewrite the fate of PKU? Results expected Aug 2027 (estimated)

Browse trials soon ready across all sponsors →

Trials to join now! 1 Not yet finished but already full! 1

Can a One-Time gene infusion rewrite the fate of PKU?

Cure Recruiting now

This early-stage trial tests a single intravenous infusion of NGGT002, a gene therapy designed to deliver a working copy of the PAH gene to adults with classic phenylketonuria (PKU). The goal is to see if this approach can safely lower phenylalanine levels in the blood, which cou…

Phase 1/2 • Sponsor: NGGT (Suzhou) Biotechnology Co., Ltd. • Aim: Cure

Last updated Aug 15, 2026 00:00 UTC